• Inicio
• freestyle libre 2
• Abbott's FreeStyle® Libre 2 iCGM Cleared in U.S. for Adults and Children with Diabetes, Achieving Highest Level of Accuracy and Performance Standards - Jun 15, 2020

Abbott's FreeStyle® Libre 2 iCGM Cleared in U.S. for Adults and Children with Diabetes, Achieving Highest Level of Accuracy and Performance Standards - Jun 15, 2020

4.7 (687) · € 8.50 · En stock

Abbott (NYSE: ABT), the worldwide leader in continuous glucose monitoring (CGM), announced today the U.S. Food and Drug Administration (FDA) cleared its next-generation FreeStyle® Libre 2

Abbott's FreeStyle® Libre 2 iCGM Cleared in U.S. for Adults and Children with Diabetes, Achieving Highest Level of Accuracy and Performance Standards

FreeStyle Libre Continuous Glucose Monitoring

FreeStyle Libre 3: World's Smallest Sensor

FreeStyle Libre 2 System (CGM)

Abbott's FreeStyle® Libre 2 iCGM Cleared in U.S. for Adults and Children with Diabetes, Achieving Highest Level of Accuracy and Performance Standards - Jun 15, 2020

ADA: Real-world data show lower A1c levels with Abbott's FreeStyle Libre CGM in Type 2 diabetes

FDA Approves FreeStyle Libre 2 iCGM System for Patients With Diabetes

Freestyle Libre 2 - Continuous Glucose Monitoring System

2 Million Patients And Beyond: Abbott's FreeStyle Libre 2 Cleared In The U.S. For Adults And Children With Diabetes

FreeStyle Libre Continuous Glucose Monitoring

FreeStyle Libre 2 Continuous Glucose Monitor

Freestyle Libre 2 - Continuous Glucose Monitoring System

FreeStyle Libre 2 System (CGM)

Abbott Releases the FreeStyle Libre 2 iCGM - Children with Diabetes